Bayer Announces New Data on KERENDIA® (Finerenone) at ACC 74th Annual Scientific Session
Whippany, N.J. – Bayer announced recently that new data from 13 analyses across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American College of Cardiology (ACC) 74th Annual Scientific Session & Expo 2025. This prestigious event is scheduled to take place in Chicago, IL, from March 29-31, 2025.
New Insights from FINEARTS-HF Trial
Ten presentations at the ACC Scientific Session will showcase new data from the pivotal Phase III FINEARTS-HF (Finerenone in Elderly Patients With Chronic Heart Failure) cardiovascular (CV) outcomes trial. KERENDIA, an investigational non-steroidal mineralocorticoid receptor antagonist (MRA), was studied for its potential in treating adult patients with chronic heart failure with reduced ejection fraction (HFrEF).
Impact on Individual Patients
For individuals diagnosed with chronic heart failure, the presentation of new data on KERENDIA could bring about significant improvements in their treatment options. The FINEARTS-HF trial demonstrated that KERENDIA reduced the risk of cardiovascular death or heart failure hospitalization by 31% compared to placebo in patients with chronic heart failure and reduced ejection fraction. These findings could lead to more effective treatments for heart failure patients and ultimately improve their quality of life.
Global Implications
The global impact of these new findings is expected to be substantial, as chronic heart failure affects millions of people worldwide. According to the World Health Organization, an estimated 23 million people suffer from heart failure globally. With the potential for more effective treatments, such as KERENDIA, the burden of heart failure on both patients and healthcare systems could be significantly reduced.
Additional Analyses
Beyond the FINEARTS-HF trial, three additional presentations will feature data from the EXPLORER-HF (Evaluation of the Effects of Finerenone in Elderly Patients With Heart Failure and Reduced Ejection Fraction) trial, which investigated the safety and efficacy of KERENDIA in older heart failure patients. An additional presentation will showcase data from the FIDELIO-DKD (Finerenone in Diabetic Kidney Disease) trial, which investigated KERENDIA’s potential in slowing the progression of chronic kidney disease in patients with type 2 diabetes mellitus and diabetic nephropathy.
Conclusion
The upcoming ACC 74th Annual Scientific Session & Expo 2025 promises to bring new insights into the treatment of chronic heart failure and diabetic kidney disease with the presentation of data from Bayer’s KERENDIA (finerenone) clinical trial program. These findings could lead to more effective treatments for millions of patients worldwide, ultimately improving their quality of life and reducing the burden on healthcare systems.
- Bayer to present new data on KERENDIA at ACC 74th Annual Scientific Session & Expo 2025
- Ten presentations to showcase new data from pivotal Phase III FINEARTS-HF trial
- KERENDIA reduced the risk of cardiovascular death or heart failure hospitalization by 31% in patients with chronic heart failure and reduced ejection fraction
- Global impact: millions of heart failure patients could benefit from more effective treatments
- Additional presentations to feature data from EXPLORER-HF and FIDELIO-DKD trials
